Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: A meta-analysis

Autor:	Ardyan Wardhana, Eka Prasetya Budi Mulia, Irma Maghfirah, Dita Aulia Rachmi, Imanita Septianda, Maya Qurota A'yun, Johanes Nugroho
Rok vydání:	2021
Předmět:	0301 basic medicine medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Physiology 030204 cardiovascular system & hematology Fibrinogen Fibrin Fibrinogen Degradation Products 03 medical and health sciences 0302 clinical medicine Physiology (medical) Internal medicine medicine Humans Methodological quality Pandemics Fibrin degradation product SARS-CoV-2 business.industry Critically ill COVID-19 Hematology Patient Outcome Assessment 030104 developmental biology Coagulation Meta-analysis Observational study Cardiology and Cardiovascular Medicine business medicine.drug
Zdroj:	Clinical Hemorheology and Microcirculation. 77:221-231
ISSN:	1875-8622 1386-0291
DOI:	10.3233/ch-200978
Popis:	INTRODUCTION: COVID-19 is a systemic infection with a significant impact on coagulation which manifests in thromboembolism. There is an unknown relationship of which coagulation profile parameter at presentation has an association with poor outcome in COVID-19. OBJECTIVE: This meta-analysis aimed to determine the relationship between fibrinogen and FDP with poor outcome in COVID-19 patients. METHODS: A systematic search of all observational studies or trials involving adult patients with COVID-19 that had any data fibrinogen or FDP on admission was carried out using the PubMed, Science Direct, Scopus, ProQuest, and MedRxiv databases. We assessed the methodological quality assessment using the NIH Quality Assessment Tool. We performed random-effects inverse-variance weighting analysis using mean difference (MD). RESULTS: A total of 17 studies (1,654 patients) were included in this meta-analysis. It revealed a higher mean of fibrinogen levels on admission in patients with severe case compared to those with non-severe case (MD = 0.69, [95% CI: 0.44 to 0.94], p <  0.05; I2 = 72%, p <  0.05). Non-survivor group had a pooled higher mean difference of fibrinogen values on admission (MD = 0.48 [95% CI: 0.13 to 0.83], p <  0.05; I2 = 38%, p = 0.18). Higher FDP on admission was found in poor outcome (composite of severity, critically ill, and mortality) compared to good outcome (4 studies, MD = 4.84 [95% CI: 0.75 to 8.93], p <  0.05; I2 = 86%, p <  0.05). CONCLUSION: Elevated fibrinogen and FDP level on admission were associated with an increase risk of poor outcome in COVID-19 patients.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07527ef6df09dd650518ace423d2e1f0 https://doi.org/10.3233/ch-200978 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.